What Promag Double Action Treats: Main Uses and Benefits

This combination product is generally used in situations involving the symptomatic relief of excess stomach acid. It is commonly used to manage acute symptomatic episodes of heartburn, acid indigestion, and sour stomach.

---

Key Symptom Management and Context

The medicine helps address symptom clusters that may become intense or disruptive, particularly the burning sensation and the upper abdominal discomfort. This support is generally applied in scenarios involving infrequent or occasional acid challenges often triggered by lifestyle factors, such as diet, where temporary assistance in symptom management is appropriate.

“The product supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Support for Acid Discomfort

Symptom Focus	Context of Use	Patient Benefit
Heartburn and Sour Stomach	Episodic acid challenges	Contributes to easing discomfort
Acid Indigestion	Short-term symptomatic support	Assists with maintaining comfort

Regulatory References

1. NIH DailyMed

The eligibility profile for Promag Double Action is strictly defined by regulatory authorities and excludes specific populations and clinical circumstances for self-treatment.

---

Eligibility and Age Restrictions

The medicine is authorized for use by adults and children 12 years of age and over. Use is not recommended for children under 12 years because the product's safety and effectiveness for this age group have not been established in official labeling.

---

Absolute Contraindications

Use is absolutely contraindicated in patients with a known allergy or hypersensitivity to the active ingredients (Famotidine, Calcium Carbonate, Magnesium Hydroxide). It is also prohibited for patients with a known allergy to other H₂-receptor antagonists due to cross-sensitivity risk, and must not be used concurrently with other acid reducers.

---

Conditional Use and Comorbidity Constraints

Eligibility is restricted for individuals with certain health conditions or symptoms. Patients with kidney disease (renal impairment) must consult a doctor before use. Furthermore, self-treatment is contraindicated if severe symptoms are present, such as vomiting blood, bloody or black stools, or trouble swallowing food. Women who are pregnant or breastfeeding are required to ask a health professional before use.

Interactions with other medicines and products

The official interaction profile for this combination medicine, which contains an H2 antagonist (Famotidine) and antacids (Calcium Carbonate, Magnesium Hydroxide), is defined by two primary pharmacokinetic domains that necessitate specific regulatory constraints.

---

Official Interaction Constraints

Co-administration is formally contraindicated with intravenous Ceftriaxone due to the risk of particulate precipitation involving the calcium component. The product label also prohibits co-administration with other acid reducers (e.g., PPIs or other H2 antagonists).

Pharmacokinetic Interactions

The acid-reducing components significantly reduce the systemic exposure of oral drugs whose absorption is pH-dependent (e.g., certain tyrosine kinase inhibitors). To mitigate this, regulatory documents establish mandatory timing separation rules for these substances and for medications that bind to cations (e.g., Bisphosphonates, Bictegravir), often requiring administration separation by two or more hours.

Metabolic interference may also occur, such as the potential for the H2 antagonist component to cause a substantial increase in the blood concentrations of CYP1A2 substrates like Tizanidine.

---

Population Considerations

Patients with renal impairment face increased risks of CNS adverse reactions due to higher Famotidine exposure and elevated magnesium toxicity due to reduced clearance of Magnesium Hydroxide. Furthermore, consumption of foods high in oxalic or phytic acid may decrease the absorption of the Calcium component.

The product's action is defined by two distinct and complementary pharmacological mechanisms: rapid neutralization and sustained suppression of new acid secretion. The Famotidine component acts as a competitive antagonist at the Histamine H2 receptors on the gastric parietal cells. By blocking these receptors, Famotidine interrupts the intracellular signaling cascade that normally activates the proton pump, resulting in a prolonged lowering of gastric fluid volume and acidity over a defined duration.

Conversely, the Calcium Carbonate and Magnesium Hydroxide components provide their effect through chemical neutralization, reacting immediately with free hydrogen ions (H^+) in the stomach to increase the intragastric pH. This high-speed buffering reduces the concentration of existing acid and causes the pH-dependent inactivation of pepsin, a digestive enzyme. These mechanisms operate synergistically: chemical neutralization drives a rapid onset by addressing the existing acid, while receptor antagonism establishes a prolonged duration through the suppression of new acid secretion.

How to Use Promag Double Action

This section details the usage and administration instructions for the Famotidine/Calcium Carbonate/Magnesium Hydroxide combination product. The medicine is classified for oral administration as a chewable tablet, and its use is guided by specific dosing and duration constraints.

---

Administration Guidelines

Instruction	Detail
Route of Administration	The product is taken orally.
Dosing Schedule	The standard dose is one (1) tablet per administration.
Preparation	The tablet must be chewed completely before swallowing.
Frequency Limit	A maximum of two (2) tablets is permitted within a 24-hour period.

---

Procedural and Age Constraints

The product is intended to be used on an as-needed (PRN) basis for symptoms, rather than a fixed daily schedule. Continuous self-medication is subject to specific time limits. Depending on established guidelines, the maximum use duration is typically defined as 14 consecutive days, though some instructions may specify a shorter maximum course of 6 days.

Administration is restricted to adults and children 12 years of age and older. No specific instructions for managing a missed dose are provided, as the usage pattern is symptom-driven. Furthermore, the label includes a note regarding the presence of Phenylalanine (2.0 to 2.2 mg per tablet), which serves as a necessary procedural instruction for individuals with Phenylketonuria (PKU).

Evidence for Symptomatic Treatment of Episodic Heartburn and Acid Indigestion

Research has explored how this product is used in conditions characterized by temporary or occasional symptoms, focusing on short-term relief in adults with episodic heartburn. Studies monitored the time taken for symptoms to change and reported how symptoms evolved. When compared against the acid-reducing component (Famotidine) used alone, findings describe patterns where the combination demonstrated a difference in the measured time to initial relief. Studies also showed patterns of prolonged effect measured over time, and research described patterns observed in patients with heartburn-related sleep disturbance. The applicability to individuals with more frequent or long-lasting acid-related conditions remains uncertain.

---

Evidence for Preventing Meal-Induced Heartburn

The product was evaluated in research scenarios focusing on episodes predictably triggered by a meal. Research examined the study pattern of administering the product prior to consumption of a known trigger meal. Findings describe patterns where the measured proportion of participants reporting symptoms after the provocative meal differed when compared to a placebo. A primary limitation is that these results reflect studies using a standardized meal, meaning there is limited information derived from the full range of real-world triggers.

---

The Study Landscape: Comparisons and Mechanism

The overall evidence landscape includes trials designed to compare the dual-action combination directly against its individual components and placebo. Studies also explored outcomes monitoring physiological strain by measuring the acid levels ( pH) inside the stomach. This evidence contributes to understanding the product’s reported patterns related to both measured onset and duration.

---

Long-Term Studies and Follow-Up Duration

Evidence is limited regarding the use of the product over long-term periods. Follow-up durations were limited, often tracking symptom changes for only a few weeks. Consequently, long-term effects are not fully established, and certainty remains low regarding the product’s pattern of use beyond the acute treatment windows.

---

Evidence in Different Patient Groups (Special Populations)

The primary clinical research focused on general adult populations experiencing temporary or occasional symptoms. Data for certain groups, such as children, pregnant individuals, or those with other comorbid conditions (existing health issues), remain insufficient. The results apply only to the populations studied, and there is limited information on how patients in different age ranges may respond.

---

What is Still Uncertain About Promag Double Action

The evidence highlights what is known—and what is still uncertain—about this study pattern. Research does not provide information on whether an individual with complex or chronic symptoms will respond similarly to the populations evaluated in the short-term studies.

Key Studies & References

1. Famotidine, Calcium Carbonate, and Magnesium Hydroxide Chewable Tablets Labeling

Common questions about Promag Double Action (FAQ)

Q: What exactly is Promag Double Action classified as in official documents?

Official product information classifies Promag Double Action as an Over-The-Counter (OTC) human drug. It contains two main components: an Acid Reducer (Famotidine) and a blend of Antacids (Calcium Carbonate and Magnesium Hydroxide). This combination means it targets stomach acid in two different ways.

Q: Where can I find the official patient information leaflet (PIL) or package insert for Promag Double Action?

The official labeling for this product, often called the Drug Facts or patient information, can be found on government-maintained drug resources. For the US, this documentation is published and searchable through the National Institutes of Health (NIH) DailyMed database. This is the authoritative source for regulatory information.

Q: How is Promag Double Action metabolized or broken down in the body, as described in regulatory information?

The components are broken down and eliminated through different processes. The Famotidine component is described as undergoing minimal processing in the liver before it is primarily removed from the body by the kidneys. The antacid components are also mainly eliminated via the kidneys.

Q: What is the primary difference in the described mechanism of action between Promag Double Action and its single-action counterpart?

The 'Double Action' refers to the two ways the product works to manage acid. The antacids provide an immediate neutralization effect on existing acid in the stomach. The Famotidine component works by reducing the amount of new acid in the stomach, providing a prolonged effect.

Q: What warnings are described regarding the use of Promag Double Action for people with severe liver or kidney impairment?

Regulatory warnings advise that a healthcare professional should be consulted before taking this product if the user has kidney disease. This caution exists because the components of the drug are primarily removed from the body by the kidneys.

Q: What information is available from official sources regarding discontinuing the use of Promag Double Action?

Official labeling directs users to stop taking the product and consult a healthcare professional if their heartburn continues, worsens, or if they find they need the product for longer than a 14-day continuous period. This duration constraint is a key procedural instruction for self-medication.

Q: Is there a time of day that official documents suggest is best for using Promag Double Action?

Official directions state that the product should be taken as-needed (PRN), specifically to relieve heartburn symptoms. Therefore, the medication is not scheduled for a specific time of day, such as morning or evening, but rather is taken when symptoms occur.

Q: What eligibility criteria are described by regulatory agencies for who is eligible to use Promag Double Action?

According to official regulatory guidance, Promag Double Action is indicated for use by adults and children 12 years of age and older. No administration is recommended for children younger than 12.

Q: What are the officially approved uses and indications for Promag Double Action?

Official product labeling indicates that the drug is approved for the relief of heartburn symptoms. This includes heartburn associated with acid indigestion and sour stomach.

Q: Is the main ingredient in Promag Double Action available in other formulations?

Yes, the active components of the product are available in other forms. Famotidine, the acid-reducing ingredient, is sold as a single medicine, and the antacid components are also available individually or in different combinations.

Q: Does Promag Double Action treat symptoms or the underlying cause of the condition?

Regulatory information describes the drug’s action as working to relieve symptoms. It functions by directly neutralizing existing stomach acid and reducing the amount of acid the stomach produces.

Q: Is there a generic version of Promag Double Action currently available on the market?

Yes, official regulatory databases list generic versions of the combination drug containing Famotidine, Calcium Carbonate, and Magnesium Hydroxide. These generic products are authorized by regulatory agencies.

Q: What information is provided on how long Promag Double Action remains detectable in the body?

The Famotidine component is recognized for providing a prolonged duration of acid reduction after administration. This sustained effect means the drug is acting in the body for an extended period.

Q: What are the most common reported side effects associated with Promag Double Action?

According to official safety data, commonly reported side effects include headache, diarrhea, or constipation. Other common reported issues include abdominal pain or general discomfort in the stomach area.

Q: Is it common to experience headache or dizziness while taking Promag Double Action?

Official sources indicate that a headache is reported as a common side effect of the product. Dizziness is listed as an uncommon side effect.

Q: Are there any rare or severe side effects described in the regulatory documents for Promag Double Action?

Yes, regulatory documents describe rare but serious reported side effects, which may include signs of a severe allergic reaction, mental or mood changes, or an irregular heartbeat. The official label instructs that the user should seek immediate medical help if these occur.

Q: Does Promag Double Action carry a specific safety warning, such as a Boxed Warning in the US?

Official US labeling confirms that Promag Double Action is classified as an Over-The-Counter (OTC) drug. The product does not carry a US FDA Boxed Warning (also known as a Black Box Warning).

Q: Does Promag Double Action interact with common painkillers?

Official warnings state that a healthcare professional should be consulted about combining the product with other medications, including common painkillers. Antacids and acid reducers may affect the absorption or safety of other prescription or over-the-counter drugs.

Q: Is there an interaction risk between Promag Double Action and moderate alcohol consumption?

Official regulatory guidance regarding lifestyle factors advises that limiting alcohol consumption may increase the effectiveness of the heartburn medication. Users can consult a healthcare professional about lifestyle choices.

Q: Can vitamins or common herbal supplements be taken safely while using Promag Double Action?

Due to the potential for interactions, official regulatory guidance states that a healthcare professional should be consulted before combining the product with any other medications or supplements. This is necessary to review the risk of altered absorption.

Q: What warnings are described in official documents regarding use of Promag Double Action with existing heart conditions?

Official warnings state that a healthcare professional must be consulted before use if the user experiences chest or shoulder pain along with other symptoms. It is also advised to consult a professional if the user has an irregular heartbeat or rhythm.

Q: Can older adults (seniors) safely use Promag Double Action, based on regulatory information?

Regulatory information indicates that older adults may experience increased sensitivity to certain side effects. This can include effects on the central nervous system, such as mental or mood changes.

Q: What official information is available about using Promag Double Action during pregnancy or while breastfeeding?

Official labeling for this product provides the warning: 'If pregnant or breast-feeding, ask a health professional before use.' This guidance ensures that a professional can assess individual risk and benefit.

Q: Is Promag Double Action considered a controlled substance by major regulatory bodies?

No. Official US information confirms that Promag Double Action is an Over-The-Counter (OTC) drug. The product is not listed as a controlled substance and has a DEA Schedule of None.

Q: What are the recommended storage conditions and shelf life for Promag Double Action?

Official directions advise that the product should be stored at controlled room temperature, typically 20^circ-25 C (68^circ-77 F). The product must also be kept sealed and protected from exposure to moisture.

Q: Is it normal for Promag Double Action to cause changes in mood or sleep patterns?

According to official safety reports, side effects that may affect sleep patterns, such as insomnia, have been reported. Additionally, some users have reported mental or mood changes, including restlessness or confusion.

Q: How is the risk of a severe allergic reaction described in the official safety profile for Promag Double Action?

The Allergy Alert warning advises against use if allergic to the components, and directs that the medication be stopped if signs of an allergic reaction occur. This is required by the official safety profile.

Q: What kind of general patient guidance is available regarding accidental overdose of Promag Double Action?

Official regulatory guidance is clear that in the event of an accidental overdose, the user should immediately seek medical help. This can be done by calling emergency services or contacting a Poison Control Center right away.

Q: How does Promag Double Action affect the central nervous system, based on pharmacologic descriptions?

Official safety documents indicate that effects on the central nervous system (CNS) have been reported. These can include common effects like headache and dizziness, and less common effects such as somnolence (drowsiness), agitation, or confusion.

Q: Does Promag Double Action list weight gain or loss as a commonly reported side effect?

While the drug is not commonly reported to cause weight changes, the official warning section notes that unexplained weight loss is a serious symptom that requires consultation with a doctor before using the product.

Official Storage and Disposal Requirements

Promag Double Action (famotidine, calcium carbonate, and magnesium hydroxide) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). To maintain the product's quality, it must be protected from moisture. The labeling specifies that brief temperature excursions up to 30 C are acceptable.

Child Safety and Handling

As a mandatory safety requirement, the medicine must always be stored out of the sight and reach of children.

Disposal of Unused Product

Disposal instructions for unused or expired tablets require following local regulatory guidelines. For non-controlled medicines without specific flush instructions, US governmental guidance recommends mixing the product with an undesirable substance, sealing it in a container, and placing it in the household trash, rather than flushing.